Financing channel feed

‘Dif­fi­cult to go pub­lic with’: Spar­ingVi­sion turns to ex­ist­ing back­ers to fund its first two oc­u­lar gene ther­a­py tri­als

3 years ago
Startups
Cell/Gene Tx

With fresh $160M, Rayze­Bio plots sprint through the clin­ic for lead ra­dio­phar­ma­ceu­ti­cal pro­gram — build­ing on No­var­tis' suc­cess

3 years ago

Forge Bi­o­log­ics con­tin­ues its hot streak with $90M round to boost gene ther­a­py man­u­fac­tur­ing ser­vices

3 years ago
Outsourcing
Manufacturing

Ace­lyrin tops its $250M crossover with new $300M cash raise from blue-chip syn­di­cate

3 years ago

Eye­ing ac­cel­er­at­ed ap­proval for Duchenne gene ther­a­py, Sarep­ta hopes to bring in $1B in bid for prof­itabil­i­ty

3 years ago

Ver­i­ly hooks $1B round amid C-suite shuf­fle

3 years ago
People
Pharma

On heels of pos­i­tive da­ta for AT­TR drug, Al­ny­lam looks to raise more cap­i­tal — near­ly $1B worth

3 years ago
R&D

Nim­bus clinch­es $125M raise via big donor-backed pri­vate fi­nanc­ing round fol­low­ing Bris­tol My­er­s' TYK2 ap­proval

3 years ago

Re­lay kicks off pub­lic of­fer­ing, seek­ing $300M af­ter lay­ing out ro­bust ES­MO da­ta

3 years ago

Fresh­ly baked: Pret­zel Ther­a­peu­tics takes out the oven mitts to drug dis­eases in the pow­er­house of the cell 

3 years ago
Startups

Deer­field backs a Penn spin­out aim­ing to shake up Parkin­son's treat­ments us­ing stem cells, brain surgery

3 years ago
Startups
Cell/Gene Tx

Go­ing be­yond pro­tein degra­da­tion, a new Broad start­up kicks in­to gear to fix pro­tein func­tion­al­i­ty

3 years ago
Startups

In­no­va­tion En­deav­ors doles out first in­vest­ment in the Joel Dud­ley era, with seed fund­ing for a small mol­e­cule start­up

3 years ago
Startups
R&D

#ES­MO22: Af­ter day filled with in­vestor, GSK ap­petite, Spring­Works brings out the da­ta for can­cer drug near­ing FDA

3 years ago
Deals
R&D

Tiny tran­scrip­tome biotech se­cures Se­ries A to ramp up au­to­mat­ed R&D ef­forts in race to­ward clin­ic

3 years ago

Over $50M in fed­er­al funds are go­ing to Vir­ginia’s phar­ma man­u­fac­tur­ing sec­tor

3 years ago
Pharma
Manufacturing

On fi­nal dash to the clin­ic, Ar­se­nal­Bio hauls in $220M for 'mod­u­lar' cell ther­a­py ap­proach

3 years ago
Cell/Gene Tx

Shang­hai-based cell ther­a­py biotech nabs new funds; Col­orado biotech nets an ac­qui­si­tion

3 years ago
China
News Briefing

French start­up Abi­vax rais­es $49M to cross the PhI­II fin­ish line for ul­cer­a­tive col­i­tis drug

3 years ago

Arc­turus touts $63M BAR­DA award for new mR­NA in­fluen­za vac­cine, hop­ing to prep against fu­ture pan­demics

3 years ago
R&D

Proven­tion Bio takes a $125M loan to ad­vance Eli Lil­ly’s once-re­ject­ed di­a­betes drug

3 years ago

A Stone Cap­i­tal-backed SPAC braves the blank check wa­ters, look­ing to grab a $150M deal

3 years ago

David Bak­er’s lab and ARCH sprout Lord of the Rings-in­spired macro­cy­cle biotech

3 years ago

Mod­er­na co-founder, ex-Bay­er CEO jump aboard Bel­gian RNA biotech, in­vest­ing in Se­ries B round

3 years ago
People
First page Previous page 47484950515253 Next page Last page
A service from the Financial Times